Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases
Location: Switzerland
Employees: 11-50
Total raised: $29.48M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
| - | VentureLab | venturelab... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.11.2025 | - | $15M | - |
| 20.07.2020 | Series B | $8.1M | - |
| 05.09.2017 | Series A | $1.26M | - |
| 23.05.2017 | - | $5.12M | - |
Mentions in press and media 26
| Date | Title | Description |
| 28.01.2026 | Zurich-based biotechs make headway | Virometix, a clinical-stage biotechnology company pioneering fully synthetic vaccines, announced positive data from the company’s Phase 1 trial of its lead asset V-212, a fully synthetic, serotype-independent, peptide-based vaccine designe... |
| 16.11.2025 | Virometix Secures $15 Million for Next-Generation Vaccine Development | Virometix, a pioneering Swiss biotech, completed a $15 million financing round. Existing investors demonstrated strong confidence. This vital capital propels V-212, their lead vaccine candidate. V-212 targets Streptococcus pneumoniae, offer... |
| 16.11.2025 | Virometix: $15 Million Financing Raised To Advance Clinical Development Of Synthetic Pneumococcal Vaccine V-212 | Virometix AG has secured a $15 million financing round from its existing shareholders, marking a significant milestone for the Swiss biotechnology company as it accelerates the clinical and developmental progress of its lead synthetic vacci... |
| 14.11.2025 | Virometix Closes $15M Financing Round | Virometix, a Schlieren, Switzerland-based biotechnology company, raised $15M in funding. Backers were not disclosed. The company intends to use the funds to: Progress new serotype-independent pneumococcal vaccine programs toward preclinical... |
| 14.11.2025 | Virometix: $15 Million Funding Completed To Advance V-212 Clinical Program And Next-Generation Synthetic Vaccines | Virometix has closed a $15 million financing round from its existing shareholders, marking a significant step forward for the Swiss biotechnology company as it accelerates the development of its fully synthetic vaccine pipeline. The investm... |
| 13.11.2025 | Virometix secures USD 15 million to advance novel pneumococcal vaccine | A Venture Kick winner and Top100 Swiss Startup, Virometix recently completed patient enrollment for the Phase I clinical trial of V-212, a synthetic, peptide-based vaccine designed to prevent Streptococcus pneumoniae infections. The vaccine... |
| 13.11.2025 | Virometix completes $15 million financing round | At the end of September, Virometix completed the enrollment of patients for the phase 1 clinical trial of its lead candidate V-212, a fully synthetic, serotype-independent, peptide-based vaccine designed to prevent Streptococcus pneumoniae... |
| 11.01.2021 | New leaders on the executive floor | |
| 11.01.2021 | New leaders on the executive floor | Battrion develops and markets its Aligned Graphite Technology (AGT) to decrease the charging time of lithium-ion batteries by up to 50%. Its co-founder Martin Ebner, who held the CEO position since 2015 has assumed the role of CTO, leaving ... |
| 23.07.2020 | Biotech startup Virometix obtains CHF 7.5 M in a series B round | Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a consider... |
Show more